Ophthalmology

Multiple medications and treatments can be used to address dry eye and dry eye disease in patients, says Karen Fernandez, MD.

Dry eye affects up to 16 million people in the US, and new treatments aim to mitigate the symptoms that can disrupt quality of life in these patients.

A new survey found that most individuals with dry eye were not sure if dry eye resolves by itself, highlighting a lack of education on the disease.

Patients with only dry eye had less severe lid margin abnormalities and orifice plugging along with tear film instability compared with those who were diagnosed with both dry eye and diabetes.

The hazard of the progression of intermediate age-related macular degeneration (iAMD) was higher in those whose complement pathways were not regulated.

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

Those who developed primary open-angle glaucoma (POAG) had lower mental health scores compared with those who had not developed the condition.

Pentacam and corneal topography were more sensitive to tear film abnormalities when measuring the curvature of the cornea in those with dry eye.

A Q&A With Douglas K. Devries, OD

A Q&A With Ryan Haumschild, PharmD, MS, MBA, CPEL

A Q&A with Alice T. Epitropoulos MD, FACS

Tear film stability, tear production, ocular surface health, and symptoms were all significantly improved with the use of punctal plugs.

A higher composite dietary antioxidant index was found to decrease the chances of American adults developing cataracts.

Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and subretinal and intraretinal fluid after switching.

Christine Funke, MD, spoke about the role of doctors in making sure their patients are receiving proper care after being diagnosed with glaucoma.

New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained Casey Koch, PharmD, from Select Health.

Christine Funke, MD, discusses how the treatment of glaucoma has evolved in her decade of experience.

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the duration is not approved.

Excessive use of digital devices and mental health issues can both contribute to the development of dry eye syndrome.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.

Michelle Hessen, OD, discusses how cyclosporine ophthalmic solution 0.09% is safe to use in patients with dry eye, as well as where future research should turn.